Compound comparison
Maridebart cafraglutide vs Tirzepatide
This page sets Maridebart cafraglutide and Tirzepatide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.
Side-by-side comparison
- Class
- Maridebart cafraglutidePeptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activityTirzepatideDual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide)
- Mechanism
- Maridebart cafraglutideIn plain terms, maridebart cafraglutide is a lab-built molecule that turns on the GLP-1 receptor to reduce appetite while blocking a second gut-hormone receptor called GIP, attached to an antibody scaffold that keeps it in the body long enough for once-monthly dosing.TirzepatideIn plain terms, tirzepatide imitates two natural gut hormones that lower blood sugar and reduce appetite.
- United States (FDA)
- Maridebart cafraglutideNot approved. Investigational only; in clinical development for obesity and type 2 diabetes and not authorized for any indication.TirzepatideApproved. Mounjaro for type 2 diabetes (May 2022); Zepbound for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024).
- European Union (EMA)
- Maridebart cafraglutideNot authorized. Investigational; no EU marketing authorisation.TirzepatideAuthorized (Mounjaro) for type 2 diabetes and weight management (marketing authorization granted September 2022).
- Australia (TGA)
- Maridebart cafraglutideNot registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia.TirzepatideRegistered on the ARTG (Mounjaro) for type 2 diabetes and for weight management, available on prescription.
- WADA
- Maridebart cafraglutideNot listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide).TirzepatideNot prohibited. Added to the WADA 2026 Monitoring Program, with markers tracked in- and out-of-competition to detect patterns of misuse; not a banned substance.
- Evidence grade
- Maridebart cafraglutideBTirzepatideA
- Tracked clinical trials
- Maridebart cafraglutide24Tirzepatide252
- Full profile
- Maridebart cafraglutideTirzepatide
| Attribute | Maridebart cafraglutide | Tirzepatide |
|---|---|---|
| Class | Peptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity | Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide) |
| Mechanism | In plain terms, maridebart cafraglutide is a lab-built molecule that turns on the GLP-1 receptor to reduce appetite while blocking a second gut-hormone receptor called GIP, attached to an antibody scaffold that keeps it in the body long enough for once-monthly dosing. | In plain terms, tirzepatide imitates two natural gut hormones that lower blood sugar and reduce appetite. |
| United States (FDA) | Not approved. Investigational only; in clinical development for obesity and type 2 diabetes and not authorized for any indication. | Approved. Mounjaro for type 2 diabetes (May 2022); Zepbound for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024). |
| European Union (EMA) | Not authorized. Investigational; no EU marketing authorisation. | Authorized (Mounjaro) for type 2 diabetes and weight management (marketing authorization granted September 2022). |
| Australia (TGA) | Not registered on the Australian Register of Therapeutic Goods (ARTG). Investigational; not approved in Australia. | Registered on the ARTG (Mounjaro) for type 2 diabetes and for weight management, available on prescription. |
| WADA | Not listed on the WADA Prohibited List and not in the 2026 Monitoring Program (which names only markers of semaglutide and tirzepatide). | Not prohibited. Added to the WADA 2026 Monitoring Program, with markers tracked in- and out-of-competition to detect patterns of misuse; not a banned substance. |
| Evidence grade | B | A |
| Tracked clinical trials | 24 | 252 |
| Full profile | Maridebart cafraglutide profile | Tirzepatide profile |
Common questions
- What is the difference between Maridebart cafraglutide and Tirzepatide?
- Maridebart cafraglutide is classified as: Peptide-antibody conjugate with GLP-1 receptor agonist and GIP receptor antagonist activity. Tirzepatide is classified as: Dual agonist of the GIP and GLP-1 receptors (incretin-based metabolic peptide). Maridebart cafraglutide is investigational and is not an approved medicine. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction.
- Is Maridebart cafraglutide or Tirzepatide approved?
- Maridebart cafraglutide is investigational and is not an approved medicine. Tirzepatide is approved for one or more medical uses in at least one major jurisdiction. Regulatory status by region is set out in the table above.
- How much clinical trial evidence is tracked for Maridebart cafraglutide and Tirzepatide?
- Peptide Science Daily tracks 24 registered clinical trials for Maridebart cafraglutide (evidence grade B) and 252 for Tirzepatide (evidence grade A).